2025-05-02 11:27:47
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Strides Pharma Science Ltd Q1FY21 consolidated PAT soars to Rs. 103.56 crore
Posted On : 2020-08-05 13:56:23( TIMEZONE : IST )
Strides Pharma Science Ltd has reported financial results for the period ended June 30, 2020.
Financial Results (Q1 FY 2020-21) - QoQ Comparison
The company has reported total income of Rs.794.10 crores during the period ended June 30, 2020 as compared to Rs.636.29 crores during the period ended March 31, 2020.
The company has posted net profit / (loss) of Rs.103.56 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.(203.92) crores for the period ended March 31, 2020.
The company has reported EPS of Rs.11.56 for the period ended June 30, 2020 as compared to Rs.(22.76) for the period ended March 31, 2020.
| Financials | Q1 FY2020-21 | Q4 FY19-20 | % Change |
| Total Income | ₹ 794.10 crs | ₹ 636.29 crs |  24.8% |
| Net Profit | ₹ 103.56 crs | ₹ (203.92) crs | 150.78% |
| EPS | ₹ 11.56 | ₹ (22.76) | 150.79% |
Financial Results (Q1 FY 2020-21) - YoY Comparison
The company has reported total income of Rs.794.10 crores during the period ended June 30, 2020 as compared to Rs.696.05 crores during the period ended June 30, 2019.
The company has posted net profit / (loss) of Rs.103.56 crores for the period ended June 30, 2020 as against net profit / (loss) of Rs.3.70 crores for the period ended June 30, 2019.
The company has reported EPS of Rs.11.56 for the period ended June 30, 2020 as compared to Rs.0.41 for the period ended June 30, 2019.
| Financials | Q1 FY2020-21 | Q1 FY2019-20 | % Change |
| Total Income | ₹ 794.10 crs | ₹ 696.05 crs | 14.09% |
| Net Profit | ₹ 103.56 crs | ₹ 3.70 crs | 2698.92% |
| EPS | ₹ 11.56 | ₹ 0.41 | 2719.51% |
Commenting on the performance, Dr R Ananthanarayanan, Managing Director & CEO, remarked, "Coming out of a challenging Q4 FY20 due to Ranitidine withdrawal, Strides has started FY21 on a positive note. We have reported strong performance across all our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment due to Covid 19. Our regulated markets growth was 22% QoQ and our emerging markets are now returning to growth after several quarters. We have delivered healthy operating leverage that led to an 920bps QoQ EBITDA margin expansion with superior cash flows.
We are proud of our global workforce for their exemplary efforts to keep our operations running during the current crisis period. We continue to pursue a "People First" approach, and the wellbeing of our employees remains our top priority.
We have demonstrated resilience and agility to adapt to the current pandemic situation. While our manufacturing and supply chain continue to remain steady without any significant disruptions, we remain cautiously optimistic on the outlook of our business for the year as the operating environment continues to evolve."
Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.467.95 as compared to the previous close of Rs. 455.15. The total number of shares traded during the day was 266027 in over 4053 trades.
The stock hit an intraday high of Rs. 471.75 and intraday low of 448.2. The net turnover during the day was Rs. 122415318.
